Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewPemetrexed is a high affinity dihydrofolate reductase inhibitor (Ki = 7 nM). Also inhibits thymidylate synthase, AICART and glycinamide ribonucleotide formyltransferase (Ki values are 109 nM, and 3.5 μM and 9.3 μM, respectively). Indirectly activates AMPK. Inhibits proliferation of cancer cell lines in vitro.
Pemetrexed is also offered as part of the Tocriscreen FDA-Approved Drugs. Find out more about compound libraries available from Tocris.
M. Wt | 427.41 |
Formula | C20H21N5O6 |
Storage | Store at +4°C |
Purity | ≥98% (HPLC) |
CAS Number | 137281-23-3 |
PubChem ID | 394493 |
InChI Key | WBXPDJSOTKVWSJ-UHFFFAOYSA-N |
Smiles | NC1=NC(C2=C(N1)NC=C2CCC3=CC=C(C(N[C@H](C(O)=O)CCC(O)=O)=O)C=C3)=O |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solvent | Max Conc. mg/mL | Max Conc. mM | |
---|---|---|---|
Solubility | |||
DMSO | 42.74 | 100 |
The following data is based on the product molecular weight 427.41. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
---|---|---|---|
1 mM | 2.34 mL | 11.7 mL | 23.4 mL |
5 mM | 0.47 mL | 2.34 mL | 4.68 mL |
10 mM | 0.23 mL | 1.17 mL | 2.34 mL |
50 mM | 0.05 mL | 0.23 mL | 0.47 mL |
References are publications that support the biological activity of the product.
Shih et al (1997) LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. 57 1116 PMID: 9067281
Rothbart et al (2010) Pemetrexed indirectly activates the metabolic kinase AMPK in human carcinomas. Cancer Res. 70 10299 PMID: 21159649
If you know of a relevant reference for Pemetrexed, please let us know.
Keywords: Pemetrexed, Pemetrexed supplier, high, affinity, dihydrofolate, reductase, inhibitor, inhibitors, DHFR, thymidylate, synthase, TS, AICART, AICARFT, aminoimidazolecarboxamide, ribonucleotide, formyltransferase, glycinamide, GARFT, chemotherapeutic, antifolate, antimetabolite, Dihydrofolate, Reductase, Other, Transferases, Thymidylate, Synthetase, 6185, Tocris Bioscience
Citations are publications that use Tocris products. Selected citations for Pemetrexed include:
Hui et al (2020) Simultaneous Control of Endogenous and User-Defined Genetic Pathways Using Unique ecDHFR Pharmacological Chaperones. Cell Chem Biol 27 622-634.e6 PMID: 32330442
Michael G et al (2021) Loss of Aurora Kinase Signaling Allows Lung Cancer Cells to Adopt Endoreplication and Form Polyploid Giant Cancer Cells That Resist Antimitotic Drugs. Cancer Res 81 400-413 PMID: 33172929
Do you know of a great paper that uses Pemetrexed from Tocris? Please let us know.
There are currently no reviews for this product. Be the first to review Pemetrexed and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
This product guide reviews some of the main areas in cancer metabolism research and lists around 150 products that can be used to investigate metabolic pathways in cancer including:
This product guide provides a review of the cell cycle and DNA damage research area and lists over 150 products, including research tools for:
This poster summarizes the main metabolic pathways in cancer cells and highlights potential targets for cancer therapeutics. Genetic changes and epigenetic modifications in cancer cells alter the regulation of cellular metabolic pathways providing potential cancer therapeutic targets.
In normal cells, each stage of the cell cycle is tightly regulated, however in cancer cells many genes and proteins that are involved in the regulation of the cell cycle are mutated or over expressed. This poster summarizes the stages of the cell cycle and DNA repair. It also highlights strategies for enhancing replicative stress in cancer cells to force mitotic catastrophe and cell death.